AbbVie (ABBV) stock

Medicines , market cap $514B

Immunology and oncology medicines

Market cap $514B

$288.82

-2.06%

As of 2:46 PM ET, delayed 15+ min · Live for Pro members

Quality Score

Exceptional

In its industry

#1of 92

Pharma

Checks firing

8of 14

Trending up

From 52-week high

-3.3%

Above the 200-day

Up:Highest Quality Score since Mar 2025. Scores before Sep 10, 2026 were rebuilt.

ABBV's Quality Score rose 4 points on Fri, Oct 30, to 23. Buying volume reached a 20-day high.

Follow ABBV's trial news. Pro members can get an alert when AbbVie files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ABBV files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2027“…next year and will be used to support regulatory submissions for lutikizumab in HS in the second half of 2027…”Filing with regulators · SEC filing · Oct 30

Why is ABBV up?

Up 1% on Oct 30 while the S&P 500 fell 2%.

Its Oct 30 results: worldwide net revenues were $17.404B, up 10.3%; global net revenues from the immunology portfolio were $9.165B, up 16.3%. It rose 1% on Oct 30.

Sources: Price history, Oct 30, 2026; Company release, Oct 30, 2026

1 more reason, free with an account →2 more reasons why ABBV rose on Oct 30, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on ABBV

Key facts on ABBV
Outperforming	Up 39% in 6 months vs the S&P's +5%
Its score	Up:Highest Quality Score since Mar 2025 Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Oct 30 Reported its quarterly results

1 more reason behind ABBV's 23, free with an account →5 more reasons behind ABBV's 23, for Pro members.

ABBV in the news

ReportFri Oct 30: sales of $17.4B; a profit of $2.37 a share. Raised its outlook for the year. Past reports ›

Fri Oct 30AbbVie Reports Third-Quarter 2026 Financial Results SEC filing 7:51 AM ET · PR Newswire and 2 more ABBV closed +1.4% that day.

Outlet counts from the GDELT Project.

What's next

Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.

1 more date ahead: dividend dates, for Pro members.

ABBV catalysts

Coming up

After its last 4 reports it closed -0.4% on average, higher 2 of 4 times.

46 past catalysts since 2020, with sizes and sources, for Pro members.Get in free →

What's next for ABBV

Next step the company has named

2H 2027“…study, including results from a 36-week blinded extension period, are expected next year and will be used to support regulatory submissions for lutikizumab in HS in the second half of 2027.”Filing with regulators · SEC filing · Oct 30

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program: Lutikizumab · Hidradenitis Suppurativa · Phase 3
Its trial: IntrepidPhase 3 · Active · 1,400 people · main data estimated Dec 2026 · NCT06468228

189 more trials, 11 with data due this year, 23 drugs past Phase 1 and 47 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 14, 2025)

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, Nicholas Donoghoe, sold 32,710 shares on Aug 14. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Robert Michael buys or sells

For Pro members: every trade, and Robert Michael’s 4 filings and quotes.

Get an alert when ABBV files news on its trialsSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why ABBV scores 23

Exceptionalfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. ABBV scores 23 today, against a median of 17.5 over its last 20 recorded sessions.

+8Chart checks 8 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Run-up adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds
News adds

No effect today: Dilution, Volatility, Cash flow, and Insider trades.

What every line is worth, and the reason behind it, on ABBV and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 2:46 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when ABBV's Quality Score turns up

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ABBV and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

ABBV has 8 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ABBV, and all 14 on every stock.Get in free →

ABBV RSI today: 62.0, above its 50-day and 200-day averages

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1462.0
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 18 sessions ago.
50-day average$269.77
The price is 7.1% above it.
200-day average$237.46
The price is 21.6% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jul 9.
ADX 1433.3
25 or more, with +DI above -DI.
Support$278.01
Swing low from Oct 22, 3.7% below the price.
Resistance$291.40
Swing high from Oct 15, 0.9% above the price.
52-week high$298.74
From Oct 30, 3.4% above the price.
52-week low$190.75
From Apr 29, 34.0% below the price.
Chart patternRising channel
Lines over the Sep 23 and Oct 15 highs and under the Oct 2 and Oct 22 lows.
Bollinger Bands (20, 2)Inside
The bands run from $268.92 to $296.66.
Volume2.0x
Against its 20-day average, for the time of day.

The deep dive on ABBV

What it does and how it makes money3 findingsFor Pro members3 findings on what ABBV does and how it makes money, for Pro members
Where it stands4 findingsFor Pro members4 findings on where ABBV stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"Litigation was filed in the United States District Court for the District of New Jersey in December 2025 and January 2026 against Apotex Inc. …" (10-Q for the quarter to Jun 30, 2026)SEC filing · Aug 3, 2026A new heading in its "Risk Factors" this year: "Pharmacy benefit managers and other supply chain intermediaries exert significant influence over pricing and patient access to our products, which could adversely affect our revenues and results of operations." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 20, 2026, against the one of Feb 14, 2025
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades ABBV, for Pro members

14 more findings on ABBV, each with its source, for Pro membersGet in free →

How ABBV ranks in Pharma

ABBV is #1 of 92 by Quality Score.

How ABBV ranks in Pharma
1	ABBVAbbVie	8/14	23
2	LLYEli Lilly	8/14	22
3	GMABGenmab	6/14	19
	ABTAbbott Laboratories		Open for its score
	ACBAurora Cannabis		Open for its score
	ZTSZoetis		Open for its score
	ZYMEZymeworks		Open for its score

When does ABBV report earnings, and what happens after?

Expected to report Wed Feb 3, before the open (in 93 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ABBV reported on Oct 30, 2026

The quarter

Sales of $17.4B, 10% more than a year ago; a profit of $2.37 a share, from $0.10.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

ABBV's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Adjusted diluted EPS	$13.95 to $13.99raised

Figures as filed (SEC filing, Oct 30)

The numbers

Market value: $514B; today
Sales: $64B; up 10.4% on the year
Free cash flow: $18B; last 12 months

Sales grew 6% a year over 5 years, fiscal 2020 to 2025.

Pays $6.92 a share a year.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ABBV: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+3.1%-2.5%+1.4%

Apr 29Jul 31Oct 30

Reported	When	Gap	Reaction	5 sessions
Oct 30, 2026Before open	Before open	+0.4%	+1.4%	open
Jul 31, 2026Before open	Before open	-1.9%	-2.5%	-5.3%
Apr 29, 2026Before open	Before open	-2.9%	+3.1%	+4.3%

ABBV closed higher after 2 of its last 4 reports.

All 4 reports, and ABBV's Quality Score going into each

ABBV sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $61B in 2025. It made a profit in each of the eight years.

ABBV share count over time

Shares: about the same count as a year ago (to Jun 30).

Shares of ABBV outstanding, as filed
Shares outstanding	As of
1.77B	Jul 27, 2026
1.77B	Apr 28, 2026
1.77B	Feb 10, 2026
1.77B	Oct 27, 2025

Offerings, shelves, and splits of ABBV, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 14, 2025

Is ABBV's dividend covered? What its financials say

Its dividends come to 67% of its free cash flow.

ABBV's dividend against its free cash flow
Dividend	$6.92 a share a year Paid 4 times a year
Paid out	About $12B a year $6.92 a share on 1.8B shares, its average count in the quarter to Jun 30, 2026
Free cash flow	$18B The last four quarters, to Jun 30, 2026
Record	Raised each of the last 5 years Against the payout a year before, each year

Insiders trading ABBV

ABBV insider trades

One insider sold $8.2M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellNicholas Donoghoe$8.2MEVP, Chief Bus/strat Officerat $250.00 on Aug 14, filed Aug 18

SellNicholas DonoghoeEVP, Chief Bus/strat Officer$8.2Mat $250.00 on Aug 14, filed Aug 18

ABBV trades by Congress and the executive branch

21 trades disclosed in the last six months. The newest:

SellRohit Khanna$15K to $50KHousetraded Sep 4, disclosed Oct 7(33 days later)

SellRohit KhannaHouse$15K to $50Ktraded Sep 4, disclosed Oct 7(33 days later)

All 21 trades on ABBV disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

ABBV's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Robert A. MichaelChairman of the Board and CEO
Scott T. ReentsEVP, Chief Financial Officer
Perry C. SiatisEVP, GC and Secretary · 2 trades
Nicholas DonoghoeEVP, Chief Bus/strat Officer · 1 trade
David Ryan PurdueSVP, Controller · 1 trade
Azita Saleki-GerhardtEVP, Chief Operations Officer
Demetris D. CrumEVP, Chief HR Officer
Jeffrey Ryan StewartEVP, Chief Commercial Officer

12 more officers and directors file at ABBV. Each page above names the rest.

See insider trades by person

Which ETFs hold ABBV?

In ETFs: ABBV is 3.4% of DGRO, 2.2% of VIG, and 2.1% of VYM, the most of the 24 funds Breakaway covers, by their holdings as filed for Jul 31, 2026.

About AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

57,000 employeesNorth Chicago, ILabbvie.com

What AbbVie says it competes with

“The markets for AbbVie's products are highly competitive.”

From its annual report, SEC filing · Feb 20, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

ABBV's score card

AbbVie (ABBV): Quality Score 23, Exceptional, #1 of 92 in Pharma, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move ABBV's score: 3 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 22Donald Trump bought ABBV$50K to $100K, disclosed Sep 22

Alerts are optional.

See ABBV's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: ABBV's Quality Score is 23 (Exceptional), #1 of 92 in Pharma. Insiders sold $8.2M in the last 6 months (Form 4).

Is ABBV a good stock to buy? What its Quality Score says

ABBV scores 23 today, which Breakaway calls Exceptional. It is #1 of 92 in Pharma by Quality Score, with 8 of 14 chart checks firing. Up 1% on Oct 30 while the S&P 500 fell 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ABBV's Quality Score?

ABBV scores 23 today, which Breakaway calls Exceptional (20 or more). That is #1 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABBV's 23.

Are insiders buying ABBV?

One insider sold $8.2M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Nicholas Donoghoe, EVP, Chief Bus/strat Officer, who sold $8.2M on Aug 14.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.